XTalks

FEBRUARY 27, 2024

Addressing the high price tag, Iovance’s commercial chief Jim Ziegler said, “Payers have expressed their appreciation for the value proposition for Amtagvi.” Clinical Promise There are currently 75 TIL immunotherapies in preclinical or clinical studies for different indications.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

pharmaphorum

OCTOBER 29, 2021

Take two recently-approved immunotherapies for triple negative breast cancer (TNBC), put them together, and what do you get? The post Gilead tags Merck for first-line triple negative breast cancer trial appeared first on. Analysts welcomed the performance but also noted it points to underlying weakness at the company.

Trials 52

Trials Sales FDA Approval Production 52

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. Cell-Based Immunotherapy vs. Immune Biologics. Immunotherapy involves leveraging components of the immune system (i.e. cells, receptors) to treat disease. asks Dr. Suri.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Delveinsight

DECEMBER 3, 2020

It has been speculated that modifications to the epigenome drive cell ageing, especially a process known as DNA methylation, by which methyl groups are tagged onto DNA. Merck chooses TriNKET cancer immunotherapy program. Merck has snapped up Dragonfly’s TriNKET cancer immunotherapy program.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

XTalks

DECEMBER 21, 2022

The multi-million-dollar price tags are largely attributable to the high R&D and manufacturing costs associated with making a gene therapy, as the raw materials for producing the therapy can be expensive. Currently, CSL Behring’s one-dose Hemophilia B gene therapy Hemgenix holds the title at $3.5 million for a single infusion.

Life Science 52

Life Science Gene Therapy Gene Clinical Trials 52

Drug Discovery World

JUNE 14, 2023

We have now our lead product in a Phase I/II study, which is a HER-2 directed tag T cell product for patients with HER-2 positive solid tumours. I’ve been with a company for more than five years now. We’ve been working on the technology for many years. I feel the excitement in cell therapy. This is not how I started out.

Research 52

Research Engineer In-Vivo Production 52

XTalks

OCTOBER 12, 2022

For ASL MR perfusion, water molecules in arterial blood from a feeder artery are magnetically tagged and tracked until they reach the region of interest. Then, the signal difference in the region of interest between the tagged images and control images can be computed to obtain cerebral blood flow (CBF) values ( Figure 3 ).

Clinical Trials 93

Clinical Trials Clinical Trials Trials Drugs 93

The Pharma Data

OCTOBER 21, 2020

The regimen chosen for the trial, conducted in Italy, included Sprycel and an immunotherapy drug called Blincyto (blinatumomab), which enlists the immune system to find and destroy cancer cells. When it came to market in 2014, the price tag for one treatment cycle was $89,000. The chemo-free approach could shorten that.

Drugs 52

Drugs Genetics Trials Research 52

The Pharma Data

OCTOBER 21, 2020

The regimen chosen for the trial, conducted in Italy, included Sprycel and an immunotherapy drug called Blincyto (blinatumomab), which enlists the immune system to find and destroy cancer cells. When it came to market in 2014, the price tag for one treatment cycle was $89,000. The chemo-free approach could shorten that.

Drugs 52

Drugs Genetics Trials Research 52

Delveinsight

FEBRUARY 25, 2021

Combining immuno-oncology treatments such as checkpoint inhibitors with other cancer-killing drugs is considered a remarkable strategy for enhancing the response rate to immunotherapy. Two genes were activated to improve the T cells’ ability to eradicate cancer cells, as reported in the journal Molecular Cell.

DNA 52

DNA In-Vivo Genetics Medicine 52

Drug Discovery World

NOVEMBER 13, 2023

On Day 3, Thursday 16 November 2023, the tracks include: the second part of machine learning for protein engineering, antibodies against membrane protein targets, engineering bispecific antibodies, next-generation immunotherapies, protein stability and formulation, and protein process development.

Protein 59

Protein Antibody Engineer Scientist 59

XTalks

JANUARY 19, 2024

This biological variability adds complexity, but with that complexity comes the power to choose the targets, the tags and the payloads and select combinations appropriate to the patient to personalize that therapy. Radiotherapies can also be combined with other therapies such as chemotherapy, immunotherapy or other targeted therapies.

DNA 66

DNA Radiology FDA Approval Development 66

Drug Discovery World

NOVEMBER 9, 2023

Thomas Valerius, MD, Professor, Stem Cell Transplantation & Immunotherapy, Christian Albrechts University of Kiel, on: ‘Neutrophil-activating therapy for the treatment of cancer’. Lei Shi, PhD, Senior Vice President, R&D, Biointron Biological, on: ‘Accelerating early discovery through htp and high-speed antibody production’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

OCTOBER 21, 2022

The main principle involves a well-defined light source such as that produced by lasers that excites fluorescent tags bound to the cells or particles present in a sample. A major breakthrough in the technology was the development of biologically active fluorescent reagents that could be detected by the instruments.

Reagent 52

Reagent Antibody Drugs Protein 52